Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo
Status:
Completed
Trial end date:
2020-11-03
Target enrollment:
Participant gender:
Summary
This is a phase 2a, randomized, double-blind, vehicle-controlled study to assess the safety,
tolerability, and systemic exposure of cerdulatinib gel, 0.37% in adults with vitiligo